Home banner
Divider
A-Z Index

Quick way to the find the information that you need...

More button
Register with FRAME

Although you do not need to register, any information you provide will be confidential and used only by FRAME to improve the website

Register button
Account Login
Forgot password?

ATLA - ISI
The Journal

 

Alternatives to Laboratory Animals - ATLA

Download latest issue button Download back issues button Subscribe to ATLA
Contact Us

Tel icon

Tel: +44 (0)115 9584740


Tel icon

Fax: +44 (0)115 9503570

Make an Enquiry

Carcinogenicity testing of pharmaceuticals in the European Union: A workshop report.


Spindler, P., van der Laan, J.W., Ceuppens, P., Harling, R., Ettlin, R. and Lima, B.S.

Drug Information Journal, 34(3), 821-828 (2000).

Recently, documents have been developed by the International Conference on Harmonisation (ICH) to guide industry on when long-term carcinogenicity bioassays are needed, testing strategy approaches, selection of the high dose, toxicokinetic evaluations, and preclinical testing of biotechnology-derived medicinal products. In the European Union (EU) the CPMP guideline on testing for carcinogenic potential was issued in 1983. Where the ICN guidelines overlap the old guideline, the industry should refer to these guidelines. Aspects of test designs and data analysis of the Committee for Proprietary Medicinal Products (CPMC) guideline need to be updated to reflect the current state of resting. This report summarizes the outcome of discussions at a DIA workshop held in September 1999 in Switzerland. Discussions included threshold concepts of nongenotoxic compounds, practical features of testing, statistical design of the study; terminal investigations, including a list of tissues to be examined histologically; principles of reporting and analysis of data; and the use of short-term carcinogenic studies, that is, aspects of the CPMP guideline which are not covered by the ICH guidelines.